Currently out of the existing stock ratings of Martin Auster, 155 are a BUY (73.81%), 11 are a SELL (5.24%), 44 are a HOLD (20.95%).

Martin Auster

Work Performance Price Targets & Ratings Chart

Analyst Martin Auster, currently employed at RAYMOND JAMES, carries an average stock price target met ratio of 65.57% that have a potential upside of 30.64% achieved within 274 days.

Martin Auster’s has documented 419 price targets and ratings displayed on 44 stocks. The coverage is on Healthcare, Industrials sectors.

Most recent stock forecast was given on ALNY, Alnylam Pharmaceuticals.

Wall Street Analyst Martin Auster

Analyst best performing recommendations are on FTSV (FORTY SEVEN).
The best stock recommendation documented was for ALNY (ALNYLAM PHARMACEUTICALS) at 7/29/2025. The price target of $370 was fulfilled within 2 days with a profit of $39.45 (11.93%) receiving and performance score of 59.67.

Average potential price target upside

ALXN Alexion Pharmaceuticals ALXO Alx Oncology Holdings ANAB AnaptysBio ARNA Arena Pharmaceuticals BMRN Biomarin Pharmaceutical ESPR Esperion Therapeutics ETTX Entasis Therapeutics Holdings FLXN Flexion Therapeutics INSM Insmed MYOK MyoKardia PTCT PTC Therapeutics RARE Ultragenyx SLDB Solid Biosciences LLC SPRB Spruce Biosciences SRPT Sarepta Therapeutics STOK Stoke Therapeutics UTHR United Therapeutics XLRN Acceleron Pharma OBSV ObsEva SA ONCE Spark Therapeutics GLTO Galecto RXDX Prometheus Biosciences INBX Inhibrx CVAC CureVac NV KURA Kura Oncology NTLA Intellia Therapeutics ALNA Allena Pharmaceuticals IRWD Ironwood Pharmaceuticals DYN Dyne Therapeutics ALNY Alnylam Pharmaceuticals BBIO BridgeBio Pharma RNA Avidity Biosciences SRRK Scholar Rock Holding Corp AL Air Lease ASND Ascendis Pharma AS CV EWTX Edgewise Therapeutics FULC Fulcrum Therapeutics GL Globe Life IRON Disc Medicine QURE Uniqure NV SEPN Septerna PDSB PDS Biotechnology Corp FTSV Forty Seven

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 28-Jul-2017

$205

$22.5 (12.33%)

5 years 5 months 27 days ago
(05-May-2021)

3/5 (60%)

$35.09 (20.65%)

938

Hold Since 03-May-2021

$173

$-9.5 (-5.21%)

$156

5 years 5 months 29 days ago
(03-May-2021)

18/29 (62.07%)

$2.73 (1.60%)

667

Hold Since 04-Feb-2021

$190

$7.5 (4.11%)

$190

5 years 6 months 6 days ago
(26-Apr-2021)

11/14 (78.57%)

$23 (13.77%)

420

Buy Since 06-Sep-2019

$175

$-7.5 (-4.11%)

$165

5 years 8 months 28 days ago
(04-Feb-2021)

3/3 (100%)

$19.41 (12.48%)

397

Buy Since 08-Feb-2018

$166

$-16.5 (-9.04%)

$179

5 years 8 months 28 days ago
(04-Feb-2021)

21/21 (100%)

$10.41 (6.69%)

711

Show more analysts

Please expand the browser size to see the chart

Which stock is Martin Auster most bullish on?

Potential upside of $150 has been obtained for ALNY (ALNYLAM PHARMACEUTICALS)

Which stock is Martin Auster most reserved on?

Potential downside of -$0 has been obtained for BBIO (BRIDGEBIO PHARMA)

What Year was the first public recommendation made by Martin Auster?

On 2017
✖

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?